中国别样茶的整理研究

别样茶是我们珍贵的非物质文化遗产,是我国各族人民长期与自然和疾病斗争的经验总结,开发研究别样茶对西部民族地区和发展“三农”经济有重要价值。民间饮用经验证明,别样茶多具有清热解毒、消食化积、利咽止咳等作用,且安全无毒。现代研究表明,别样茶多含有黄酮类、多酚类、萜类、挥发油等化学成分,具有抗氧化、抗菌、降血脂、降血糖、降血压、免疫促进、抗肿瘤、保肝与抗炎等多种药理活性。别样茶是防治慢性代谢性疾病的重要研究对象。笔者对中国别样茶的种类进行了初步考证,并对其传统应用进行了考察,结合现代化学成分和药理活性的研究,为中国别样茶的进一步研究与开发奠定了基础。     

海南虎刺枝叶中化学成分及其抗类风湿性关节炎活性研究

目的 研究茜草科虎刺属植物海南虎刺Damnacanthus hainanensis枝叶中的化学成分及其抗类风湿性关节炎活性。方法 综合运用硅胶柱色谱、反相硅胶柱色谱、Sephadex LH-20凝胶柱色谱以及制备型HPLC等色谱技术进行系统分离和纯化,根据分离得到化合物的理化性质及其波谱数据,并通过与文献中报道的波谱数据进行比对,鉴定化合物的结构;采用MTS法通过对分离得到化合物的体外抑制滑膜细胞增殖的活性进行测试以评价其抗类风湿性关节炎活性。结果 从海南虎刺枝叶的甲醇提取物中分离得到了18个化合物,分别鉴定为naucleidinal（1）、1,2,3,4-tetrahydronorharman-1-one（2）、19-O-methyl-3,14-dihydroangustoline（3）、latifoliamide B（4）、latifoliamide D（5）、bacilsubteramide A（6）、vinmajine I（7）、naucleofficine D（8）、1-甲氧甲酰-β-咔巴啉（9）、naphthisoxazol A（10）、1,6-dihydroxy-2-methyl-9,10-anthraquinone（11）、rubiadin-1-methyl ether（12）、1,3,6-trihydroxy-2-methoxymethyl-9,10-anthraquinone（13）、3,6-dihydroxy-2-hydroxymethyl-9,10-anthra quinone（14）、7-羟基色原酮（15）、5,7-二羟基色原酮（16）、6,4''-dihydroxy-3''-methoxyaurone（17）和farnisin（18）。抗类风湿性关节炎活性评价结果表明,化合物11～14、17和18对滑膜成纤维MH7A细胞增殖抑制活性的半数抑制浓度（median inhibition concentration,IC₅₀）值为（8.93±0.09）～（152.58±0.32）μmol/L。结论 所有化合物均为首次从虎刺属植物中分离得到。化合物11～14、17和18表现出了较为显著的抗类风湿性关节炎活性。     

Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial

ABSTRACT

Objectives: Intravenous thrombolysis and thrombectomy are recommended for patients whose stroke onsets are within first 6 h, and very few options are available for patients whose stroke onset is more than 6 h, which includes most ischemic stroke patients. Human urinary kallidinogenase (HUK) showed potential clinical benefits in acute ischemic stroke patients. This study aims to investigate the safety and clinical benefits of HUK in ischemic stroke patients.

Patients and methods: Patients were recruited for a multicenter double-blind, placebo-controlled phase II b and phase III trial. Neurophysiological outcomes were assessed by the European Stroke Scale (ESS) and the functional outcomes were assessed by the activity of daily living scale (ADL). Safety was monitored by recording adverse events.

Results: The improvements in ESS scores and ADL scores in the HUK group were significantly greater than that in patients receiving placebo. Furthermore, HUK treatment was also associated with a lower rate of disable, according to ADL. HUK-related adverse events occurred at a low rate, in 1.73% of HUK-treated patients.

Conclusion: HUK is safe and provides potential clinical benefits as a treatment for acute ischemic stroke. Further large post-marketing observational studies are needed.     

Impact of Frailty on Outcomes After Primary and Revision Total Hip Arthroplasty

Background

Frailty and disability from arthritis are closely intertwined and little is known about the impact of frailty on total hip arthroplasty (THA) outcomes. We hypothesized that higher preoperative frailty is associated with more adverse events following THA.

护理服务在医疗公益活动中的作用及几点感受

护理人员在医疗公益活动中承担着各个环节的工作,在保障活动有序进行发挥着重要作用,有序的护理服务能够使医疗公益活动顺利进行,回顾2009年6月~2013年11月医疗公益活动中的护理工作。     

3-取代吲哚-2-酮类化合物的设计、合成及抗肿瘤活性研究

目的设计合成对微管蛋白和血管内皮细胞生长因子受体2(VEGFR-2)激酶具有双重抑制作用的3-取代吲哚-2-酮类化合物,考察其体外抑瘤活性。方法以取代的苯胺为起始原料,经缩合、环合、还原、取代等反应制得系列目标化合物,并考察该系列化合物对微管蛋白和肿瘤细胞的抑制活性。结果共合成了11个新的目标化合物。实验结果显示,化合物j9对微管蛋白和VEGFR-2激酶具有双重抑制活性。所有目标化合物对3种肿瘤细胞株均有中等强度的抑制活性。结论该类化合物是一类具有多靶点作用的抗肿瘤化合物。     

The effect of dance-based mind-motor activities on the quality of life in the patients recovering from COVID-19: A protocol for systematic review and meta-analysis

Background:Since the outbreak of coronavirus disease 2019 (COVID-19), with the improvement of diagnosis and treatment level in various countries, more and more patients have been discharged after systematic treatment. In order to effectively promote the overall recovery of patients’ physical and mental function and quality of life (QOL), the focus of clinical work should be gradually shifted to rehabilitation treatment. Dance-based mind-motor activities were defined as coordinated upright mind-motor movements that emphasize dynamic balance, structured through music or an inner rhythm (e.g., breathing) and distinctive instructions or choreography, and that involve social interaction. It has positive effects on motor function, lung function, psychological mood and other aspects, so it can be used as a safe alternative therapy for patients recovering from COVID-19. At present, there are no relevant articles for systematic review.Methods:From its inception until March 2021, we will conduct a comprehensive electronic search, including Cochrane Library, MEDLINE, PubMed, Springer, EMBASE, Chinese Science Citation Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Scientific Journal Database, Wan-fang database. Two independent researchers will conduct article retrieval, screening, quality assessment, and data analysis through the Review Manager (V. 5.3.5).Results:The results of this study will evaluate the effectiveness and safety of dance-based mind-motor activities for the improvement of QOL in COVID-19 patients during the recovery period.Conclusion:The conclusion of the study will provide an evidence to judge whether dance-based mind-motor activities is effective and safe for COVID-19 in recovery period.Ethics and dissemination:This protocol will not evaluate individual patient information or infringe patient rights and therefore does not require ethical approval.PROSPERO registration number:CRD42021232995.     

New legal requirements for submission of product information to poisons centres in EU member states

Introduction: In the past eight years, the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) has been intensively involved in a European Commission led process to develop EU legislation on the information of hazardous products that companies have to notify to EU Poisons Centres (or equivalent “appointed bodies”). As a result of this process, the Commission adopted Regulation (EU) No 2017/542, amending the CLP Regulation by adding an Annex on harmonised product submission requirements.

Harmonised mixture information requirements: Detailed and consistent information on the composition of the hazardous product will become available to EU Poisons Centres (PC). The information will be submitted by companies to PCs (or equivalent “appointed bodies”) using a web-based software application or in-house software. Two new important features are introduced. Firstly, to be able to rapidly identify the product formula, a Unique Formula Identifier (UFI) on the product label links to the submitted information. Secondly, for better comparability of reports on poisonings between EU member states, a harmonised Product Categorisation System will specify the intended use of a product. Rapid product identification and availability of detailed composition information will lead to timely and adequate medical intervention. This may lead to considerable reduction in healthcare costs.

Additionally, for companies trading across the EU, costs of submission of this information will be reduced significantly.

Next steps: From 2017, an implementation period has started, consisting of a three-year period for stakeholders to implement the new requirements, followed by a gradual applicability for consumer products (2020), professional products (2021) and industrial use-only products (2024). Technical tools to generate the electronic format and the UFI together with guidance documents are expected to be made available by the end of 2017 by the European Chemicals Agency (ECHA). Guidance on interpretation of legal text and ECHA helpdesk support are planned to be ready at the end of 2018.